Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Endocrine Disorders
Published in: BMC Endocrine Disorders 1/2023

Open Access 01-12-2023 | Insulins | Research

Circulating levels of adropin and diabetes: a systematic review and meta-analysis of observational studies

Authors: Sepideh Soltani, Sara Beigrezaei, Mahsa Malekahmadi, Cain C. T. Clark, Shima Abdollahi

Published in: BMC Endocrine Disorders | Issue 1/2023

Login to get access

Abstract

Objective

Adropin, a newly identified regulatory protein has garnered attention given its potential role in metabolism regulation, especially glucose metabolism and insulin resistance. However, studies on the association between adropin and type 2 diabetes mellitus (T2DM) are equivocal. The aim of this study is to assess the association between serum adropin levels and T2DM using a systematic review and meta-analysis of observational studies.

Methods

PubMed, Scopus, ISI Web of science, and Google Scholar were searched, up to August 2022, for studies that reported the association between serum levels of adropin in adults with T2DM compared to a control group without diabetes. A random-effect model was used to compute the pooled weighted mean difference (WMD) with 95% confidence intervals (CI).

Results

Meta-analysis of 15 studies (n = 2813 participants) revealed that the serum adropin concentrations were significantly lower in patients with T2DM compared with the control group (WMD= -0.60 ng/mL, 95% CI: -0.70 to -0.49; I2 = 99.5%). Subgroup analysis also found lower concentration of adropin in patients with T2DM who were otherwise healthy compared to a control group (n = 9; WMD=-0.04 ng/ml, 95% CI= -0.06 to -0.01, p = 0.002; I2 = 96.4).

Conclusions

Our study showed adropin levels are lower in patients with diabetes compared to a control group without diabetes. However, the limitations of observational studies challenge the validity of the results, and further investigations are needed to confirm the veracity of these findings and additionally explore possible mechanisms.
Literature
1.
DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, et al. Type 2 diabetes mellitus. Nat reviews Disease primers. 2015;1:1–22.
2.
Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Reviews Endocrinol. 2018;14:88.CrossRef
3.
Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. The Lancet. 2017;389:2239–51.CrossRef
4.
Saran R, Robinson B, Abbott KC, Agodoa LY, Albertus P, Ayanian J, et al. US renal data system 2016 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2017;69:A7–A8.PubMedPubMedCentralCrossRef
5.
6.
Kumar KG, Trevaskis JL, Lam DD, Sutton GM, Koza RA, Chouljenko VN, et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metabol. 2008;8:468–81.CrossRef
7.
Butler AA, Zhang J, Price CA, Stevens JR, Graham JL, Stanhope KL, et al. Low plasma adropin concentrations increase risks of weight gain and metabolic dysregulation in response to a high-sugar diet in male nonhuman primates. J Biol Chem. 2019;294:9706–19.PubMedPubMedCentralCrossRef
8.
Yolbaş S, Kara M, Kalaycı M, Yıldırım A, Gündoğdu B, Aydın S et al. ENHO gene expression and serum adropin level in rheumatoid arthritis and systemic lupus erythematosus. 2018.
9.
Butler AA, Tam CS, Stanhope KL, Wolfe BM, Ali MR, O’Keeffe M, et al. Low circulating adropin concentrations with obesity and aging correlate with risk factors for metabolic disease and increase after gastric bypass surgery in humans. J Clin Endocrinol Metabolism. 2012;97:3783–91.CrossRef
10.
Stein LM, Yosten GL, Samson WK. Adropin acts in brain to inhibit water drinking: potential interaction with the orphan G protein-coupled receptor, GPR19. Am J Physiology-Regulatory Integr Comp Physiol. 2016;310:R476–R80.CrossRef
11.
Rao A, Herr DR. G protein-coupled receptor GPR19 regulates E-cadherin expression and invasion of breast cancer cells. Biochim et Biophys Acta (BBA)-Molecular Cell Res. 2017;1864:1318–27.CrossRef
12.
Thapa D, Stoner MW, Zhang ML, Xie BX, Manning JR, Guimaraes D, et al. Adropin regulates pyruvate dehydrogenase in cardiac cells via a novel GPCR-MAPK-PDK4 signaling pathway. Redox Biol. 2018;18:25–32.PubMedPubMedCentralCrossRef
13.
Wong C-M, Wang Y, Lee JTH, Huang Z, Wu D, Xu A et al. Adropin is a brain membrane-bound protein regulating physical activity via the NB-3/Notch signaling pathway in mice. 2014;289:25976–86.
14.
Lovren F, Pan Y, Quan A, Singh KK, Shukla PC, Gupta M et al. Adropin is a novel regulator of endothelial function. 2010;122:S185-S92.
15.
Ganesh-Kumar K, Zhang J, Gao S, Rossi J, McGuinness OP, Halem HH, et al. Adropin deficiency is associated with increased adiposity and insulin resistance. Obesity. 2012;20:1394–402.PubMedCrossRef
16.
Gao S, McMillan RP, Zhu Q, Lopaschuk GD, Hulver MW, Butler AA. Therapeutic effects of adropin on glucose tolerance and substrate utilization in diet-induced obese mice with insulin resistance. Mol metabolism. 2015;4:310–24.CrossRef
17.
Choi HN, Yim JE. Plasma adropin as a potential marker Predicting obesity and obesity-associated Cancer in korean patients with type 2 diabetes Mellitus. J Cancer Prev. 2018;23:191–6.PubMedPubMedCentralCrossRef
18.
Gao S, McMillan RP, Jacas J, Zhu Q, Li X, Kumar GK, et al. Regulation of substrate oxidation preferences in muscle by the peptide hormone adropin. Diabetes. 2014;63:3242–52.PubMedPubMedCentralCrossRef
19.
Koves TR, Ussher JR, Noland RC, Slentz D, Mosedale M, Ilkayeva O, et al. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metabol. 2008;7:45–56.CrossRef
20.
Jasaszwili M, Billert M, Strowski MZ, Nowak KW, Skrzypski M. Adropin as a Fat-Burning hormone with multiple functions—review of a Decade of Research. Molecules. 2020;25:549.PubMedPubMedCentralCrossRef
21.
Jasaszwili M, Wojciechowicz T, Billert M, Strowski MZ, Nowak KW, Skrzypski MJM et al. Effects of adropin on proliferation and differentiation of 3T3-L1 cells and rat primary preadipocytes. 2019;496:110532.
22.
Ozcan U, Cao Q, Yilmaz E, Lee A-H, Iwakoshi NN, Ozdelen E et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. 2004;306:457–61.
23.
Gao S, Ghoshal S, Zhang L, Stevens JR, McCommis KS, Finck BN, et al. The peptide hormone adropin regulates signal transduction pathways controlling hepatic glucose metabolism in a mouse model of diet-induced obesity. J Biol Chem. 2019;294:13366–77.PubMedPubMedCentralCrossRef
24.
Wu L, Fang J, Chen L, Zhao Z, Luo Y, Lin C, et al. Low serum adropin is associated with coronary atherosclerosis in type 2 diabetic and non-diabetic patients. Clin Chem Lab Med. 2014;52:751–8.PubMedCrossRef
25.
Kume T, Calan M, Yilmaz O, Kocabas G, Yesil P, Temur M, et al. A possible connection between tumor necrosis factor alpha and adropin levels in polycystic ovary syndrome. J Endocrinol Investig. 2016;39:747–54.CrossRef
26.
Bousmpoula A, Kouskouni E, Benidis E, Demeridou S, Kapeta-Kourkouli R, Chasiakou A, et al. Adropin levels in women with polycystic ovaries undergoing ovarian stimulation: correlation with lipoprotein lipid profiles. Gynecol Endocrinol. 2018;34:153–6.PubMedCrossRef
27.
Hosseini A, Shanaki M, Emamgholipour S, Nakhjavani M, Razi F, Golmohammadi T. Elevated serum levels of adropin in patients with type 2 diabetes mellitus and its association with insulin resistance. J Biology Today’s World. 2016;5:44–9.
28.
Ugur K, Oz B, Ozkan Y, Sener SY, Orhan B, Aydin S, editors. Microalbuminuria by concentration serum and urine levels of adropin in patients with type 2 diabetes mellitus. Endocrine Abstracts; 2015.
29.
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst reviews. 2015;4:1.CrossRef
30.
31.
Egger M, Davey-Smith G, Altman D. Systematic reviews in health care: meta-analysis in context. John Wiley & Sons; 2008.
32.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.PubMedCrossRef
33.
34.
Alaaraji SFT. Correlation of calprotectin with galectin-3, adropin and CTLA-4 in iraqi rheumatoid arthritis patients. Int J Pharm Res. 2020;12:932–9.
35.
Bolayir HA, Kivrak T, Gunes H, Bolayir A, Karaca I. Adropin and circadian variation of blood pressure. Kardiologia Polska. 2018;76:776–82.PubMedCrossRef
36.
Caf F, Algul S, Koyun M. Investigation of the irisin, preptin and adropin levels in the blood serum of Alburnus tarichi. Cell Mol Biol. 2017;63:95–9.PubMedCrossRef
37.
Cao JF, Wang MS, Bian CY, Tao YF, You T, Xu WT, et al. Association between serum adropin and subclinical atherosclerosis in patients with hyperlipidemia. Int J Clin Exp Med. 2019;12:9351–8.
38.
Conte D, Nordio M, Ronnanelli F, Manganelli F, Giovenco P, Dondero F, et al. Role of seminal prostaglandins in male fertility. II. Effects of prostaglandin synthesis inhibition on spermatogenesis in man. J Endocrinological Investigation: Official J Italian Soc Endocrinol. 1985;8:289–91.CrossRef
39.
Eraslan E, Topdagi O, Tanyeli A, Guler MC, Sebin E, Sebin SO, et al. Can insulin-like Protein-3 and Adropin be a new marker in Hepatocellular Carcinoma? Acta Physiol. 2018;225:34.
40.
Eser Karlidag G, Arslan Solmaz O. Are adropin, apelin, elabela, asprosin and betatrophin biomarkers for chronic hepatitis and staging of fibrosis? Biotech Histochem. 2020;95:152–9.PubMedCrossRef
41.
Grzegorzewska AE, Niepolski L, Mostowska A, Warchoł W, Jagodziński PP. Involvement of adropin and adropin-associated genes in metabolic abnormalities of hemodialysis patients. Life Sci. 2016;160:41–6.PubMedCrossRef
42.
Gu XS, Li H, Zhu XY, Gu HB, Chen JC, Wang LC et al. Inverse Correlation Between Plasma Adropin and ET-1 Levels in Essential Hypertension A Cross-Sectional Study.Medicine. 2015;94.
43.
Gulen B, Eken C, Kucukdagli OT, Serinken M, Kocyigit A, Kılıc E, et al. Adropin levels and target organ damage secondary to high blood pressure in the ED. Am J Emerg Med. 2016;34:2061–4.PubMedCrossRef
44.
Gundogar H, Ozsoy B, Uzunkaya M, Senyurt SZ, Erciyas K. Effect of Peri-Implant Disease on Adropin levels: a cross-sectional pilot study. Eur J Ther. 2020;26:61–5.CrossRef
45.
Kaluzna M, Hoppe K, Schwermer K, Ibrahim AY, Pawlaczyk K, Ziemnicka K. Adropin and irisin levels in relation to nutrition, body composition, and insulin resistance in patients with end-stage renal disease on chronic hemodialysis and peritoneal dialysis. Polskie Arch Medycyny Wewnetrznej-Polish Archives Intern Med. 2016;126:474–82.
46.
Lu Z, Chen X, Wang S. Associations of serum adropin level with severity of coronary artery disease and slow Flow in patients with Non-ST-elevation ACS. Chin Gen Pract. 2020;23:2895–900.
47.
Niu YX, Wang XL, Wang DQ, Jiang XF. Changes of serum vitamin D levels in infertile patients with polycystic ovarian syndrome and its significance. Int J Clin Exp Med. 2020;13:3442–8.
48.
Oruc CU, Akpinar YE, Dervisoglu E, Amikishiyev S, Salmaslioglu A, Gurdol F, et al. Low concentrations of adropin are associated with endothelial dysfunction as assessed by flow-mediated dilatation in patients with metabolic syndrome. Clin Chem Lab Med. 2017;55:139–44.PubMedCrossRef
49.
Rao A, Herr DR. G protein-coupled receptor GPR19 regulates E-cadherin expression and invasion of breast cancer cells. Biochim et Biophys Acta - Mol Cell Res. 2017;1864:1318–27.CrossRef
50.
Sanchis-Gomar F, Alis R, Rampinini E, Bosio A, Ferioli D, La Torre A, et al. Adropin and apelin fluctuations throughout a season in professional soccer players: are they related with performance? Peptides. 2015;70:32–6.PubMedCrossRef
51.
Tuna BG, Atalay PB, Altunbek M, Kalkan BM, Dogan S. Effects of chronic and intermittent calorie restriction on adropin levels in breast Cancer. Nutr Cancer. 2017;69:1003–10.PubMedCrossRef
52.
Wang HD, Wang XJ, Cao Y, Han WX, Guo YJ, Yang GS et al. Association of polymorphisms of preptin, irisin and adropin genes with susceptibility to coronary artery disease and hypertension.Medicine. 2020;99.
53.
Zhang C, Zhao L, Xu W, Li J, Wang B, Gu X, et al. Correlation of serum adropin level with coronary artery disease. Natl Med J China. 2014;94:1255–7.
54.
Grzegorzewska AE, Niepolski L, Swiderska MK, Mostowska A, Stolarek I, Warchol W, et al. ENHO, RXRA, and LXRA polymorphisms and dyslipidaemia, related comorbidities and survival in haemodialysis patients. BMC Med Genet. 2018;19:194.PubMedPubMedCentralCrossRef
55.
Yosaee S, Khodadost M, Esteghamati A, Speakman JR, Shidfar F, Nazari MN, et al. Metabolic syndrome patients have lower levels of Adropin when compared with healthy Overweight/Obese and lean subjects. Am J Men’s Health. 2017;11:426–34.CrossRef
56.
Ogurel T, Ogurel R, Topuz M, Ornek N, Ornek K. Plasma adropin level in patients with pseudoexfoliation. Int Ophthalmol. 2016;36:737–42.PubMedCrossRef
57.
Sen H, Erbag G, Binnetoglu E, Eroglu M, Turkon H, Tekin SZ, et al. Adropin levels in polycystic ovary syndrome patients. J Clin Anal Med. 2017;8:23–6.
58.
Kuliczkowska-Płaksej J, Mierzwicka A, Jończyk M, Stachowska B, Urbanovych A, Bolanowski M. Adropin in women with polycystic ovary syndrome. Endokrynologia Polska. 2019;70:151–6.PubMedCrossRef
59.
Bozic J, Borovac JA, Galic T, Kurir TT, Supe-Domic D, Dogas Z. Adropin and inflammation biomarker levels in male patients with obstructive sleep apnea: a link with glucose metabolism and sleep parameters. J Clin Sleep Med. 2018;14:1109–18.PubMedPubMedCentralCrossRef
60.
Wang B, Xue Y, Shang F, Ni S, Liu X, Fan B et al. Association of serum adropin with the presence of atrial fibrillation and atrial remodeling.Journal of Clinical Laboratory Analysis. 2019;33.
61.
Hamdi RA, Abas HN, Alsaeed FAA. Role of adropin in women with polycystic ovary syndrome. Indian J Public Health Res Dev. 2019;10:809–14.CrossRef
62.
Zhao LP, You T, Chan SP, Chen JC, Xu WT. Adropin is associated with hyperhomocysteine and coronary atherosclerosis. Experimental and Therapeutic Medicine. 2016;11:1065–70.PubMedCrossRef
63.
Korkmaz S, Sayılan Özgün G. Serum adropin levels in psoriasis vulgaris and its relation with metabolic parameters. Turk J Med Sci. 2019;49:110–5.PubMedPubMedCentral
64.
Demircelik B, Kurtul A, Ocek H, Cakmak M, Cetin M, Ureyen C, et al. The relationship between adropin levels and the slow coronary Flow Phenomenon. Indian J Clin Biochem. 2015;30:412–7.CrossRef
65.
Gheit AE, Atef RE, El Deeb MM, Badawi OS, Alshenawy GA, Elwan HA. WM, et al. Unique novel role of Adropin in the gastric Ulcer in a rotenone-induced rat model of Parkinson’s disease. ACS chemical neuroscience; 2020.
66.
Akcilar R, Emel Kocak F, Simsek H, Akcilar A, Bayat Z, Ece E, et al. The effect of adropin on lipid and glucose metabolism in rats with hyperlipidemia. Iran J basic Med Sci. 2016;19:245–51.PubMedPubMedCentral
67.
Altintas O, Kumas M, Altintas MO. Neuroprotective effect of ischemic preconditioning via modulating the expression of adropin and oxidative markers against transient cerebral ischemia in diabetic rats. Peptides. 2016;79:31–8.PubMedCrossRef
68.
Aydin MA, Aydogdu N, Tastekin E, Kandemir N, Yavuz OY, Kudaibergenova A. Investigation of the relation of Nesfatin-1 and adropin with blood pressure in experimental hypertension model. Neuroendocrinology. 2018;107:32.
69.
Aydin S, Aydin S, Kuloglu T, Kalayci M, Yilmaz M, Çakmak T, et al. Elevated adropin: a candidate diagnostic marker for myocardial infarction in conjunction with troponin-I. Peptides. 2014;58:91–7.PubMedCrossRef
70.
Aydin S, Eren MN, Kuloglu T, Aydin S, Yilmaz M, Gul E, et al. Alteration of serum and cardiac tissue adropin, copeptin, irisin and TRPM2 expressions in DOX treated male rats. Biotech Histochem. 2015;90:197–205.PubMedCrossRef
71.
Billert M, Jasaszwili M, Strowski M, Nowak KW, Skrzypski M. Adropin suppresses insulin expression and secretion in INS-1E cells and rat pancreatic islets.Journal of physiology and pharmacology: an official journal of the Polish Physiological Society. 2020;71.
72.
Bremer AA, Stanhope KL, Graham JL, Cummings BP, Ampah SB, Saville BR, et al. Fish oil supplementation ameliorates fructose-induced hypertriglyceridemia and insulin resistance in adult male rhesus macaques. J Nutr. 2014;144:5–11.PubMedCrossRef
73.
Chao HC, Tsai PF, Lee SC, Lin YS, Wu MC. Effects of Myricetin-Containing ethanol solution on High-Fat Diet Induced obese rats. J Food Sci. 2017;82:1947–52.PubMedCrossRef
74.
Chen X, Sun X, Shen T, Chen Q, Chen S, Pang J, et al. Lower adropin expression is associated with oxidative stress and severity of nonalcoholic fatty liver disease. Free Radic Biol Med. 2020;160:191–8.PubMedCrossRef
75.
Gulmez A, Celiker H, Bicim S, Aydin S, Kuloglu T. The investigation of the Therapeutic Effect of Adropin on Gentamicin-Induced Experimental Nephropathy. Turkish Nephrol Dialysis Transplantation J. 2018;27:240–8.
76.
Kedzierski W, Cywniska A, Wawak T, Janczarek I, Wilk I, Kowalik S. Plasma apelin concentration in exercised horses: preliminary study. J Equine Veterinary Sci. 2019;80:16–9.CrossRef
77.
Mohamed FH, Ozer C. The effect of systemic Adropin treatment on levels of oxidant and antioxidant of Cardiac muscle in Diabetic rats. Acta Physiol. 2019;227:60.
78.
Pawlowska-Olszewska M, Puzio I, Tymicki G, Kalisz G, Sroka-Bartnicka A, Blicharz-Kania A et al. Adropin, nesfatin-1 and angiotensin ii receptor expression in the abdominal aorta in ovariectomized rats after nesfatin-1 treatment.Journal of Physiology and Pharmacology. 2019;70.
79.
Skugor A, Kjos NP, Sundaram AYM, Mydland LT, Anestad R, Tauson AH, et al. Effects of long-term feeding of rapeseed meal on skeletal muscle transcriptome, production efficiency and meat quality traits in norwegian landrace growing-finishing pigs. PLoS ONE. 2019;14:e0220441.PubMedPubMedCentralCrossRef
80.
Thapa D, Xie B, Manning JR, Zhang M, Stoner MW, Huckestein BR et al. Adropin reduces blood glucose levels in mice by limiting hepatic glucose production.Physiological Reports. 2019;7.
81.
Kuloglu T, Aydin S. Immunohistochemical expressions of adropin and ınducible nitric oxide synthase in renal tissues of rats with streptozotocin-ınduced experimental diabetes. Biotech Histochem. 2014;89:104–10.PubMedCrossRef
82.
Wu LZ, Fang J, Yuan X, Xiong C, Chen LL. Adropin reduces hypoxia/reoxygenation-induced myocardial injury via the reperfusion injury salvage kinase pathway. Experimental and Therapeutic Medicine. 2019;18:3307–14.PubMedPubMedCentral
83.
Muter J, Alam MT, Vrljicak P, Barros FSV, Ruane PT, Ewington LJ, et al. The glycosyltransferase EOGT regulates adropin expression in decidualizing human endometrium. Endocrinology. 2018;159:994–1004.PubMedCrossRef
84.
Sato K, Yamashita T, Shirai R, Shibata K, Okano T, Yamaguchi M et al. Adropin contributes to anti-atherosclerosis by suppressing monocyte-endothelial cell adhesion and smooth muscle cell proliferation.International Journal of Molecular Sciences. 2018;19.
85.
Alizadeh R, Golestani N, Moradi L, Rezaeinezhad N. Effect of aerobic exercise with maximal fat oxidation intensity, on adropin and insulin resistance among overweight women.Iranian Journal of Endocrinology and Metabolism. 2018;20.
86.
Celik HT, Akkaya N, Erdamar H, Gok S, Kazanci F, Demircelik B, et al. The Effects of Valsartan and Amlodipine on the levels of Irisin, Adropin, and Perilipin. Clin Lab. 2015;61:1889–95.PubMedCrossRef
87.
Wei S, Gao Q, Wang E. Effects of high- intensity interval training on plasma adropin concentration and endothelial function in male obese youth. Chin J Rehabilitation Med. 2019;34:1058–64.
88.
Stevens JR, Kearney ML, St-Onge MP, Stanhope KL, Havel PJ, Kanaley JA, et al. Inverse association between carbohydrate consumption and plasma adropin concentrations in humans. Obesity. 2016;24:1731–40.PubMedCrossRef
89.
St-Onge MP, Shechter A, Shlisky J, Tam CS, Gao S, Ravussin E, et al. Fasting plasma adropin concentrations correlate with fat consumption in human females. Obesity. 2014;22:1056–63.PubMedCrossRef
90.
Zarrati M, Raji Lahiji M, Salehi E, Yazdani B, Razmpoosh E, Shokouhi Shoormasti R, et al. Effects of Probiotic Yogurt on serum Omentin-1, Adropin, and Nesfatin-1 concentrations in overweight and obese participants under low-calorie Diet. Probiotics and Antimicrobial Proteins; 2018.
91.
Li S, Sun J, Hu W, Liu Y, Lin D, Duan H, et al. The association of serum and vitreous adropin concentrations with diabetic retinopathy. Ann Clin Biochem. 2019;56:253–8.PubMedCrossRef
92.
Palizban A-A, Yazdani A-H, Jahanbani-Ardakani H. Role of rs7903146 polymorphism and adropin serum level in patients with diabetes mellitus; a case–control study from Isfahan,Iran. Archives of Physiology and Biochemistry. 2019:1–4.
93.
Li B, Li N, Guo S, Zhang M, Li J, Zhai N, et al. The changing features of serum adropin, copeptin, neprilysin and chitotriosidase which are associated with vascular endothelial function in type 2 diabetic retinopathy patients. J Diabetes Complicat. 2020;34:107686.CrossRef
94.
Hu W, Chen L. Association of serum adropin concentrations with diabetic nephropathy. Mediators of inflammation. 2016;2016.
95.
Kutlu O, Altun Ö, Dikker O, Aktaş Ş, Özsoy N, Arman Y, et al. Serum adropin levels are reduced in adult patients with nonalcoholic fatty liver disease. Med Principles Pract. 2019;28:463–9.CrossRef
96.
Ali HA, Abbas HJ, Naser NA. Preptin and adropin levels as new predictor in women with polycystic ovary syndrome. J Pharm Sci Res. 2018;10:3005–8.
97.
Shelest B. Correlation of adropin, chemerin and inflammation in hypertensive patients with type 2 diabetes mellitus and obesity. Kardiologija v Belarusi. 2018;10:766–74.
98.
Zang H, Jiang F, Cheng X, Xu H, Hu X. Serum adropin levels are decreased in chinese type 2 diabetic patients and negatively correlated with body mass index. Endocr J. 2018;65:685–91.PubMedCrossRef
99.
Aydin P, Uzuncakmak SK, Tor IH, Bilen A, Ozden A. Comparison of serum adropin levels in patients with diabetes Mellitus, COVID-19, and COVID-19 with diabetes Mellitus. Eurasian J Med. 2022;54:197–201.PubMedPubMedCentralCrossRef
100.
Es-Haghi A, Al-Abyadh T, Mehrad-Majd H. The clinical value of serum Adropin Level in Early Detection of Diabetic Nephropathy. Kidney Blood Press Res. 2021;46:734–40.PubMedCrossRef
101.
Li N, Xie GM, Zhou BA, Qu AJ, Meng H, Liu J et al. Serum Adropin as a Potential Biomarker for Predicting the Development of Type 2 Diabetes Mellitus in Individuals With Metabolic Dysfunction-Associated Fatty Liver Disease.Frontiers in Physiology. 2021;12.
102.
Shah N, Anand P, Kumar S, Kulkarni P. Evaluation of serum adropin levels in type 2 diabetic patients and its correlation with insulin resistance: a tertiary care teaching hospital-based study. J Datta Meghe Inst Med Sci Univ. 2021;16:658–61.CrossRef
103.
Zhang XK, Li BX, Li N, Zhai N, Zhang YL, Liu LF, et al. Changes of serum adropin protein and neprilysin levels in patients with type 2 diabetic retinopathy and analysis of influening factors. Int Eye Sci. 2020;20:504–8.
104.
Akcilar R, Kocak F, Simsek H, Akcilar A, Bayat Z, Ece E, et al. Antidiabetic and hypolipidemic effects of adropinin streoptozotocin-induced type 2 diabetic rats. Bratisl Lek Listy. 2016;117:100.PubMed
105.
Kuo FY, Cheng K-C, Li Y, Cheng J-T, Tsai C-C. Promotion of Adropin Expression by Hyperglycemia Is Associated with STAT3 Activation in Diabetic Rats. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2020;13:2269.
106.
Aydin S, Kuloglu T, Aydin S, Eren MN, Yilmaz M, Kalayci M, et al. Expression of adropin in rat brain, cerebellum, kidneys, heart, liver, and pancreas in streptozotocin-induced diabetes. Mol Cell Biochem. 2013;380:73–81.PubMedCrossRef
107.
Inal ZO, Erdem S, Gederet Y, Duran C, Kucukaydin Z, Kurku H, et al. The impact of serum adropin and ischemia modified albumin levels based on BMI in PCOS. Endokrynologia Polska. 2018;69:135–41.PubMed
108.
Ghoshal S, Stevens JR, Billon C, Girardet C, Sitaula S, Leon AS, et al. Adropin: an endocrine link between the biological clock and cholesterol homeostasis. Mol metabolism. 2018;8:51–64.CrossRef
109.
Erman H, Ozdemir A, Sitar ME, Cetin SI, Boyuk BJJoIM. Role of serum adropin measurement in the assessment of insulin resistance in obesity. 2021;69:1318–23.
110.
Topuz M, Celik A, Aslantas T, Demir AK, Aydin S, Aydin S. Plasma adropin levels predict endothelial dysfunction like flow-mediated dilatation in patients with type 2 diabetes mellitus. J Investig Med. 2013;61:1161–4.PubMedCrossRef
111.
Soltani S, Kolahdouz-Mohammadi R, Aydin S, Yosaee S, Clark CC, Abdollahi SJH. Circulating levels of adropin and overweight/obesity: a systematic review and meta-analysis of observational studies. 2021:1–8.
112.
Celik E, Yilmaz E, Celik O, Ulas M, Turkcuoglu I, Karaer A, et al. Maternal and fetal adropin levels in gestational diabetes mellitus. J Perinat Med. 2013;41:375–80.PubMedCrossRef
113.
Kheirandish-Gozal L, Gileles-Hillel A, Alonso-Álvarez ML, Peris E, Bhattacharjee R, Terán-Santos J, et al. Effects of adenotonsillectomy on plasma inflammatory biomarkers in obese children with obstructive sleep apnea: a community-based study. Int J Obes. 2015;39:1094–100.CrossRef
114.
Metelli S, Chaimani AJE. -bmh. Challenges in meta-analyses with observational studies. 2020;23:83 – 7.
Metadata
Title
Circulating levels of adropin and diabetes: a systematic review and meta-analysis of observational studies
Authors
Sepideh Soltani
Sara Beigrezaei
Mahsa Malekahmadi
Cain C. T. Clark
Shima Abdollahi
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2023
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-023-01327-0

Other articles of this Issue 1/2023

BMC Endocrine Disorders 1/2023 Go to the issue

Case report

Central diabetes insipidus: a late sequela of BNT162b2 SARS-CoV-2 mRNA vaccine?

Research

Comparing the effectiveness of metformin with lifestyle modification for the primary prevention of type II diabetes: a systematic review and meta-analysis

Research

Internet analytics of an innovative digital educational resource of type 1 diabetes HelloType1 in local languages for people living with diabetes families and healthcare professionals in Southeast Asia

Research

The association between healthy beverage index and sarcopenic obesity among women with overweight and obesity: a cross-sectional study

Research

Prevalence and risk factor of diabetes among the elderly people in West Bengal: evidence-based LASI 1st wave

Case report

Ectopic sphenoidal ACTH-secreting adenoma revealed by 11C Methionine PET scan: case report
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits